Healthcare · Medical Specialties
Stryker Corporation
$317.01 -1.79 (-0.56%) Pre-market $323.00 (+1.32%) ≈ ₹29,752 a share
Key numbers
- Market value
- $120.68B
- P/E (TTM)
- 33.8
- Forward P/E
- 20.2
- EPS (TTM)
- $9.39
- Dividend yield
- 1.11%
- Beta
- 0.77
- Day range
- $314.57 – $323.61
- 52-week range
- $267.00 – $389.33
- Volume
- 599,495
- 10-day avg volume
- $3.90M
- Revenue (TTM)
- $26.30B
- EBITDA (TTM)
- $7.58B
- Gross margin
- 65.7%
- Net margin
- 13.8%
- Return on equity
- 16.0%
- Debt / equity
- 63.7%
- Price / sales
- 4.59
- Shares out
- 380.69M
Quarterly results
Results for each quarter
Last 12 quarters from 10-Q and 10-K filings with the US SEC. Q4 = full year minus the first three quarters. Hover a bar to see the number.
Revenue and net income
Revenue · QoQ (vs last quarter)
Revenue · YoY (vs a year ago)
Net income · QoQ (vs last quarter)
Net income · YoY (vs a year ago)
| US$ | Dec 23 | Mar 24 | Jun 24 | Sep 24 | Dec 24 | Mar 25 | Jun 25 | Sep 25 | Dec 25 | Mar 26 | Jun 26 | Sep 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.82B | $5.24B | $5.42B | $5.49B | $6.44B | $5.87B | $6.02B | $6.06B | $7.17B | $6.02B | $6.59B | $6.52B |
| Cost of revenue | $2.11B | $1.91B | $2.01B | $1.98B | $2.26B | $2.12B | $2.18B | $2.21B | $2.54B | $2.21B | $2.09B | $2.27B |
| Gross profit | $3.70B | $3.33B | $3.42B | $3.52B | $4.17B | $3.74B | $3.84B | $3.85B | $4.63B | $3.81B | $4.50B | $4.25B |
| Gross margin | 63.7% | 63.6% | 63.0% | 64.0% | 64.9% | 63.8% | 63.8% | 63.6% | 64.5% | 63.3% | 68.3% | 65.2% |
| Research & development | $350.00M | $368.00M | $363.00M | $377.00M | $358.00M | $405.00M | $407.00M | $410.00M | $401.00M | $413.00M | $434.00M | $433.00M |
| Selling, general & admin | $1.91B | $1.84B | $1.83B | $1.89B | $2.12B | $2.30B | $2.08B | $2.05B | $2.23B | $2.28B | $2.23B | $2.31B |
| Operating income | $1.26B | $972.00M | $1.05B | $1.09B | $581.00M | $837.00M | $1.11B | $1.14B | $1.80B | $936.00M | $1.66B | $1.03B |
| Operating margin | 21.6% | 18.5% | 19.4% | 19.7% | 9.0% | 14.3% | 18.5% | 18.7% | 25.2% | 15.5% | 25.2% | 15.9% |
| Interest expense | — | — | — | — | — | $137.00M | $159.00M | $157.00M | $154.00M | $148.00M | $141.00M | $143.00M |
| Pre-tax income | $1.23B | $923.00M | $998.00M | $1.04B | $528.00M | $764.00M | $1.02B | $1.03B | $1.71B | $850.00M | $1.56B | $997.00M |
| Income tax | $83.00M | $135.00M | $173.00M | $209.00M | $-18.00M | $110.00M | $132.00M | $170.00M | $856.00M | $105.00M | $288.00M | $244.00M |
| Net income | $1.14B | $788.00M | $825.00M | $834.00M | $546.00M | $654.00M | $884.00M | $859.00M | $849.00M | $745.00M | $1.28B | $753.00M |
| Net margin | 19.7% | 15.0% | 15.2% | 15.2% | 8.5% | 11.1% | 14.7% | 14.2% | 11.8% | 12.4% | 19.4% | 11.5% |
| EPS (diluted) | $2.98 | $2.05 | $2.14 | $2.16 | $1.41 | $1.69 | $2.29 | $2.22 | $2.20 | $1.93 | $3.30 | $1.96 |
Income statement
Results for each year
8 fiscal years from the company's 10-K filings with the US SEC.
Revenue, gross profit and net income
Revenue · YoY (vs a year ago)
Net income · YoY (vs a year ago)
EPS (diluted) · YoY (vs a year ago)
| US$ | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $13.60B | $14.88B | $14.35B | $17.11B | $18.45B | $20.50B | $22.60B | $25.12B |
| Revenue growth | — | 9.4% | -3.6% | 19.2% | 7.8% | 11.1% | 10.2% | 11.2% |
| Cost of revenue | $4.66B | $5.19B | $5.29B | $6.14B | $6.87B | $7.44B | $8.16B | $9.05B |
| Gross profit | $8.94B | $9.70B | $9.06B | $10.97B | $11.58B | $13.06B | $14.44B | $16.07B |
| Gross margin | 65.7% | 65.1% | 63.1% | 64.1% | 62.8% | 63.7% | 63.9% | 64.0% |
| Research & development | $862.00M | $971.00M | $984.00M | $1.24B | $1.45B | $1.39B | $1.47B | $1.62B |
| Selling, general & admin | $5.10B | $5.36B | $5.36B | $6.43B | $6.39B | $7.11B | $7.69B | $8.65B |
| Operating income | $2.54B | $2.71B | $2.22B | $2.58B | $2.84B | $3.89B | $3.69B | $4.89B |
| Operating margin | 18.7% | 18.2% | 15.5% | 15.1% | 15.4% | 19.0% | 16.3% | 19.5% |
| Depreciation & amortisation | $966.00M | $1.04B | $1.08B | $1.27B | $1.28B | $1.34B | $1.43B | $1.57B |
| Interest expense | — | — | — | — | — | $363.00M | $409.00M | $607.00M |
| Pre-tax income | $2.36B | $2.56B | $1.95B | $2.28B | $2.68B | $3.67B | $3.49B | $4.51B |
| Income tax | $-1.20B | $479.00M | $355.00M | $287.00M | $325.00M | $508.00M | $499.00M | $1.27B |
| Tax rate | -50.8% | 18.7% | 18.2% | 12.6% | 12.1% | 13.8% | 14.3% | 28.1% |
| Net income | $3.55B | $2.08B | $1.60B | $1.99B | $2.36B | $3.17B | $2.99B | $3.25B |
| Net margin | 26.1% | 14.0% | 11.1% | 11.7% | 12.8% | 15.4% | 13.2% | 12.9% |
| EPS (diluted) | $9.34 | $5.48 | $4.20 | $5.21 | $6.17 | $8.25 | $7.76 | $8.40 |
Balance sheet
Assets and debt
At each fiscal year end.
Equity, debt and cash
Shareholders' equity · YoY (vs a year ago)
| US$ | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $3.62B | $4.34B | $2.94B | $2.94B | $1.84B | $2.97B | $3.65B | $4.01B |
| Short-term investments | — | $88.00M | $81.00M | $75.00M | $84.00M | $82.00M | $91.00M | $89.00M |
| Current assets | $9.73B | $11.06B | $9.71B | $10.02B | $10.28B | $12.52B | $14.85B | $14.76B |
| Total assets | $27.23B | $30.17B | $34.33B | $34.63B | $36.88B | $39.91B | $42.97B | $47.84B |
| Current liabilities | $4.81B | $4.40B | $5.04B | $4.55B | $6.30B | $7.92B | $7.62B | $7.79B |
| Long-term debt | $8.49B | $10.23B | $13.23B | $12.47B | $11.86B | $10.90B | $12.19B | $14.86B |
| Short-term debt | $1.37B | $859.00M | $761.00M | $7.00M | $1.19B | $2.09B | $1.41B | $1.00B |
| Total debt | $9.86B | $11.09B | $13.99B | $12.48B | $13.05B | $13.00B | $13.60B | $15.86B |
| Total liabilities | $15.50B | $17.36B | $21.25B | $19.75B | $20.27B | $21.32B | $22.34B | $25.42B |
| Shareholders' equity | $11.73B | $12.81B | $13.08B | $14.88B | $16.62B | $18.59B | $20.63B | $22.42B |
| Current ratio | 2.02 | 2.51 | 1.93 | 2.20 | 1.63 | 1.58 | 1.95 | 1.89 |
| Debt / equity | 0.84 | 0.87 | 1.07 | 0.84 | 0.79 | 0.70 | 0.66 | 0.71 |
| Return on equity | 30.3% | 16.3% | 12.2% | 13.4% | 14.2% | 17.0% | 14.5% | 14.5% |
Cash flow
Cash coming in and going out
Free cash flow = cash from operations minus capital spending. Shareholder returns = dividends + buybacks.
Free cash flow and shareholder returns
Operating cash flow · YoY (vs a year ago)
Free cash flow · YoY (vs a year ago)
| US$ | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | $2.61B | $2.19B | $3.28B | $3.26B | $2.62B | $3.71B | $4.24B | $5.04B |
| Capital spending | $-572.00M | $-649.00M | $-487.00M | $-525.00M | $-588.00M | $-575.00M | $-755.00M | $-761.00M |
| Free cash flow | $2.04B | $1.54B | $2.79B | $2.74B | $2.04B | $3.14B | $3.49B | $4.28B |
| FCF margin | 15.0% | 10.4% | 19.4% | 16.0% | 11.0% | 15.3% | 15.4% | 17.1% |
| Stock-based pay | $119.00M | $127.00M | $142.00M | $171.00M | $168.00M | $205.00M | $229.00M | $243.00M |
| Cash from investing | $-2.86B | $-1.46B | $-4.70B | $-859.00M | $-2.92B | $-962.00M | $-3.00B | $-4.87B |
| Cash from financing | $1.33B | $3.00M | $-11.00M | $-2.37B | $-749.00M | $-1.59B | $-525.00M | $113.00M |
| Dividends paid | $-703.00M | $-778.00M | $-863.00M | $-950.00M | $-1.05B | $-1.14B | $-1.22B | $-1.28B |
| Share buybacks | $-300.00M | $-307.00M | $0 | $0 | — | — | — | — |
About
About Stryker Corporation
Stryker Corporation is an American multinational medical technologies corporation based in Portage, Michigan, United States. The company's products are used for medical surgery and neurotechnology, which include surgical equipment, patient and caregiver safety technologies, endoscopy systems, and patient handling, emergency medical equipment, and intensive care disposable products, as well as neurosurgical, neurovascular and oral and maxillofacial surgery implant products; and orthopedic surgery, which includes implants used in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries. Stryker's products are sold in over 75 countries and are used by 150 million patients annually. In 2024, 75% of the company's revenues came from the United States.
From Wikipedia (CC BY-SA 4.0).
Company details
- Company name
- Stryker Corporation
- Ticker
- SYK
- Exchange
- NYSE
- ISIN
- US8636671013
- SEC CIK
- 0000310764
- Sector
- Healthcare
- Industry
- Medical Specialties
- SEC industry (SIC)
- Surgical & Medical Instruments & Apparatus (3841)
- Incorporated in
- Michigan
- Financial year ends
- 31 December
- Filer type
- Large accelerated filer
- Latest annual report (10-K)
- 11 Feb 2026
- CEO
- Kevin A. Lobo
- Chair
- Kevin A. Lobo
- Headquarters
- Portage
- Address
- 1941 Stryker Way, Portage, Mi 49002
- Founded
- 1946
- Employees
- 56,000
- Trades in
- US dollars (USD)
- Website
- stryker.com
News
Latest news
From Google News; each link opens the publisher's story.
Peers
Others in Healthcare
Quotes from CNBC (may be delayed), financials from SEC EDGAR, profile from global-stock-logos (MIT). Information only, not investment advice.